TISIDB

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein Note=Colocalizes with KCNB1 at the plasma membrane (PubMed:19074135).
Domain	PF02214 BTB/POZ domain PF00520 Ion transport protein
Function	Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 (PubMed:19074135).

> Gene Ontology [ TOP ]
Biological Process	GO:0006813 potassium ion transport GO:0010959 regulation of metal ion transport GO:0015672 monovalent inorganic cation transport GO:0022898 regulation of transmembrane transporter activity GO:0032409 regulation of transporter activity GO:0032412 regulation of ion transmembrane transporter activity GO:0034762 regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0043266 regulation of potassium ion transport GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:0071804 cellular potassium ion transport GO:0071805 potassium ion transmembrane transport GO:1901016 regulation of potassium ion transmembrane transporter activity GO:1901379 regulation of potassium ion transmembrane transport GO:1902259 regulation of delayed rectifier potassium channel activity GO:1904062 regulation of cation transmembrane transport GO:2001257 regulation of cation channel activity
Molecular Function	GO:0005216 ion channel activity GO:0005244 voltage-gated ion channel activity GO:0005249 voltage-gated potassium channel activity GO:0005251 delayed rectifier potassium channel activity GO:0005261 cation channel activity GO:0005267 potassium channel activity GO:0015077 monovalent inorganic cation transmembrane transporter activity GO:0015079 potassium ion transmembrane transporter activity GO:0015267 channel activity GO:0022803 passive transmembrane transporter activity GO:0022832 voltage-gated channel activity GO:0022836 gated channel activity GO:0022838 substrate-specific channel activity GO:0022843 voltage-gated cation channel activity GO:0046873 metal ion transmembrane transporter activity
Cellular Component	GO:0008076 voltage-gated potassium channel complex GO:0034702 ion channel complex GO:0034703 cation channel complex GO:0034705 potassium channel complex GO:1902495 transmembrane transporter complex GO:1990351 transporter complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-112316: Neuronal System R-HSA-1296071: Potassium Channels R-HSA-1296072: Voltage gated Potassium channels

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KCNG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KCNG1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KCNG1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.768	0.14
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-1.017	0.229
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.601	0.455
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.34	0.68
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.565	0.718
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.48	0.447
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.91	0.255
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.502	0.652
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.713	0.158
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.449	0.455
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.503	0.533
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.704	0.0162

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KCNG1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KCNG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KCNG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KCNG1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KCNG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KCNG1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KCNG1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KCNG1
Name	potassium channel, voltage gated modifier subfamily G, member 1
Aliases	Kv6.1; kH2; KCNG; potassium voltage-gated channel, subfamily G, member 1; potassium channel KH2; potassium c ......
Chromosomal Location	20q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KCNG1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KCNG1